More news – Page 5
-
NewsCAR-T therapy could treat severe autoimmune diseases, shows study
Earlier intervention in severe autoimmune diseases may help prevent complications following previous ineffective treatments.
-
NewsGilead strengthens ADC capabilities with $5bn Tubulis acquisition
Deal expands the companies’ existing two-year partnership and builds Gilead’s oncology pipeline.
-
NewsSurface bioburden study offers insight on non-sterile manufacturing
Microbial load fell within the predefined limit, suggesting contamination was controlled during a single time point.
-
NewsTrump imposes 100 percent tariff on imported pharmaceuticals
US administration proffers leeway on tariffs for some drugs, with UK exports benefitting from exemption under the recent UK-US partnership.
-
NewsFDA approves Lilly’s small molecule obesity pill Foundayo
New GLP-1 therapy Foundayo is Eli Lilly’s second obesity medicine to be authorised for use in the US.
-
NewsEditas Medicine’s gene-edited therapy reni-cel sees early clinical success
The CRISPR–Cas12a autologous stem cell therapy improved total haemoglobin levels in participants with sickle cell disease.
-
NewsLilly advances neuroscience portfolio with $7.8bn acquisition of Centessa
Acquisition includes a potential best-in-class asset for excessive daytime sleepiness, broadening Lilly’s capabilities into sleep medicine.
-
NewsUCB’s TK2d therapy Kygevvi approved by European Commission
Authorisation of the small molecule therapy in the EU represents a new option for thymidine kinase 2 deficiency, builds on earlier US FDA approval.
-
NewsFramework supports microbiota assessment in cleanroom changing rooms
Case study presents a potential benchmarking model for microbial trend data and a data presentation format for pharmaceutical cleanrooms.
-
NewsHolistic automation for data integrity, usability and sustainability
IMA Active explores how interconnected, human-centric systems that implement advanced automation and usability can enhance operational efficiency and sustainability in tablet manufacturing.
-
NewsNovo Nordisk’s Awiqli first FDA-approved once-weekly basal insulin
The type 2 diabetes injection reduces administration frequency from daily to once per week, enhancing convenience for patients.
-
NewsMerck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals
Deal strengthens Merck’s oncology portfolio with addition of a potential best-in-class oral TKI for chronic myeloid leukaemia.
-
NewsUCB positions new Georgia biologics facility as future US manufacturing hub
The biopharmaceutical company’s latest manufacturing venture represents one of the largest investments in Georgia’s history.
-
NewsAstraZeneca’s Imfinzi wins EU-first immunotherapy approval in early GI cancers
The approval represents the pharmaceutical company’s third perioperative approval in Europe for an Imfinzi-based regimen.
-
NewsGilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines
T cell engager gamgertamig could redefine standard of care for immune-mediated diseases.
-
NewsNanoparticle-exosome innovation could enhance cell therapy manufacturing
Novel, end-to-end process improves all four steps of exosome production simultaneously, supporting the design of more effective treatments.
-
NewsBMS wins dual immunotherapy-first approvals in classical Hodgkin Lymphoma
Expanded EU and US approvals for Bristol Myers Squibb’s Opdivo (nivolumab) position combination therapy as frontline option for the common blood cancer.
-
NewsNovartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition
Deal to help address the significant unmet need in HR+/HER2- breast cancer and other advanced solid tumours.
-
NewsPennsylvania to house new actinium-225 manufacturing facility
Construction of TerraPower Isotopes’ cGMP facility increases its production capacity for the rare isotope, helping to boost global access to targeted alpha therapies.
-
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.